Clinical trial · no report yet · Phase 3
POLARGO
A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- NCT04182204 ↗
- Completed
- Hoffmann-La Roche
- 57 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 19 | |
| Podcasts | 19 | |
| X threads | 18 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Open-Label, Multicenter, Randomized, Study Evaluating the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab Plus Gemcitabine Plus Oxaliplatin (R-GEMOX) Versus R-GEMOX Alone in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- Polatuzumab Vedotin; Rituximab; Gemcitabine; Oxaliplatin
- Arms
- Pola-R-GemOx (Stage 1) · Experimental
- Pola-R-GemOx (Stage 2) · Experimental
- R-GemOx (Stage 2) · Active comparator
- Enrollment
- 270
- Primary outcomes
- Stage 1: Number of Participants With Adverse Events (AEs)
- Stage 1: Number of Participants With Peripheral Neuropathy (PN)
- Stage 2: Overall Survival (OS)
- Sponsor
- Hoffmann-La Roche
- Start
- Feb 7, 2020
- Primary completion
- Nov 29, 2024
- Results posted
- Yes
- Registry record
- NCT04182204 · updated Dec 22, 2025
Publications
linked from the registry- Matasar M, Li Z, Vassilakopoulos TP, Sancho JM, Viardot A, McMillan A, Dal MS, Pereira J, Kim JS, Qiu L, Batlevi CL, Ibrahim R, Hernandez J, McCall B, Jiang Y, Yan M, Harris W, Musick L, Haioun C. Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial. J Clin Oncol. 2026 Sep;44(25):2435-2446. doi: 10.1200/JCO-25-02849. Epub 2026 Jul 6. PubMed 42407012